Doxepin (Silenor, Sinequan) and Ketamine Therapy | Tovani Health
Silenor (Doxepin) (also: Sinequan) — Tricyclic antidepressant (TCA)
Verdict at Tovani Health
Sedating TCA; we time sessions around the sedation, not around serotonin syndrome.
Doxepin is compatible with KAP. It is strongly antihistaminic and centrally sedating; we schedule sessions in the morning if you take it at bedtime. Older SSRI-style serotonin syndrome monitoring does not apply with ketamine, which is not meaningfully serotonergic.
If you take Silenor regularly and are considering at-home ketamine therapy, the combination is safe with monitoring or dose adjustment. This page covers the brief pharmacologic context and what we do at intake.
How Silenor interacts with ketamine
Doxepin has strong antihistaminic activity that drives sedation at any dose. Ketamine sessions add their own dissociative-sedation window. Sedation stacking is the main consideration; ketamine does not raise serotonin in a way that compounds doxepin's serotonergic component.
What we do at intake
Tell us the dose and bedtime timing. Low-dose doxepin (3-6 mg) for sleep is a smaller concern than depression-range doses (75-300 mg).
Bottom line
Doxepin is compatible with KAP. It is strongly antihistaminic and centrally sedating; we schedule sessions in the morning if you take it at bedtime. Older SSRI-style serotonin syndrome monitoring does not apply with ketamine, which is not meaningfully serotonergic.
Frequently Asked Questions
I take low-dose doxepin for insomnia. Is that an issue?
Low-dose doxepin (3-6 mg) at bedtime is rarely a problem if your session is in the morning.
Ready to find out if at-home ketamine fits your situation?
We’ll note that you’re on Silenor (Doxepin) at intake. The eligibility check takes 5 minutes and gives you an honest answer about whether at-home ketamine fits your specific situation.
FL and NJ residents only. Benjamin Soffer, DO — Tovani Health.
Sources
The verdict and clinical guidance on this page are based on the following peer-reviewed literature and FDA prescribing information.
- Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review. Veraart JKE, Smith-Apeldoorn SY, Bakker IM, et al.. International Journal of Neuropsychopharmacology. 2021. PMID: 34170315
Systematic review of pharmacodynamic interactions between ketamine and psychiatric medications used in depression treatment.
- Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis. Alnefeesi Y, Chen-Li D, Krane E, et al.. Journal of Psychiatric Research. 2022. PMID: 35688035
Meta-analysis of 2,665 patients across 79 studies — 45% response and 30% remission with ketamine in treatment-resistant depression.
Clinically reviewed
Reviewed by Benjamin Soffer, DO on May 15, 2026. Dr. Soffer is a board-certified physician (American Board of Internal Medicine) licensed in Florida and New Jersey, prescribing at-home ketamine therapy through Tovani Health.
This page is general information about how this medication interacts with at-home ketamine therapy at Tovani Health. It is not a substitute for medical advice from your prescribing physician about your specific situation. Always discuss medication changes with the doctor who prescribed them.